Contact
Please use this form to send email to PR contact of this press release:
Calithera Biosciences Initiates a Randomized Phase 2 Combination Trial of CB-839 in Patients with Renal Cell Carcinoma
TO:
Please use this form to send email to PR contact of this press release:
Calithera Biosciences Initiates a Randomized Phase 2 Combination Trial of CB-839 in Patients with Renal Cell Carcinoma
TO: